November 9, 2012 — Svelte Medical Systems announced it received conditional approval from the U.S. Food and Drug Administration (FDA) to begin a pivotal study for the Svelte coronary stent integrated delivery system (IDS).

November 9, 2012 — The U.S. Food and Drug Administration (FDA) recently cleared Bolton Medical’s Relay Thoracic Stent Graft with Plus Delivery System.

November 9, 2012 — A study found that the use of rosuvastatin prior to angioplasty did not influence the levels of troponin I, a sensitive indicator of muscle damage. Results were presented at the 24th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation (CRF).

November 9, 2012 — Bristol-Myers Squibb Co. and Pfizer Inc. announced that the reductions in stroke or systemic embolism, major bleeding, and mortality demonstrated with Eliquis compared to warfarin in the ARISTOTLE trial were consistent across a wide range of stroke and bleeding risk scores in patients with nonvalvular atrial fibrillation. These results of a subanalysis from the ARISTOTLE clinical trial were published in The Lancet.

Toshiba’s advanced radiation dose reduction technology, Adaptive Iterative Dose Reduction 3D (AIDR 3D), is now available on all new Aquilion CT systems, from the 16-detector row Aquilion RXL to the 320-detector row Aquilion ONE. AIDR 3D is Toshiba’s third-generation iterative dose reconstruction software incorporating significant system enhancements by reducing radiation dose compared with conventional scanning. 

For more information: www.medical.toshiba.com

Toshiba will showcase Spot Fluoro, a dose management tool for Infinix-i vascular X-ray systems. Spot Fluoro allows clinicians to view a region of anatomy using live fluoroscopy while viewing the Last Image Hold surrounding area, resulting in lower dose and a larger image display area than offered by previous technology.

Amplatzer Structural Heart Occulder Closure Device RESPECT Clinical Trial

November 8, 2012 — Results of the RESPECT clinical trial, presented at TCT 2012, indicates that using an investigational medical device to close a PFO, or “hole in the heart,” may be superior to medical management alone in the prevention of a repeated stroke.
Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now